2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD3
  5. CD3 Substrate

CD3 Substrate

CD3 Substrate (1):

Cat. No. Product Name Effect Purity
  • HY-P99430
    Alnuctamab
    		Substrate 99.89%
    Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).